These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

332 related articles for article (PubMed ID: 36076237)

  • 21. THZ1 targeting CDK7 suppresses STAT transcriptional activity and sensitizes T-cell lymphomas to BCL2 inhibitors.
    Cayrol F; Praditsuktavorn P; Fernando TM; Kwiatkowski N; Marullo R; Calvo-Vidal MN; Phillip J; Pera B; Yang SN; Takpradit K; Roman L; Gaudiano M; Crescenzo R; Ruan J; Inghirami G; Zhang T; Cremaschi G; Gray NS; Cerchietti L
    Nat Commun; 2017 Jan; 8():14290. PubMed ID: 28134252
    [TBL] [Abstract][Full Text] [Related]  

  • 22. CDK7 inhibitor suppresses tumor progression through blocking the cell cycle at the G2/M phase and inhibiting transcriptional activity in cervical cancer.
    Zhong S; Zhang Y; Yin X; Di W
    Onco Targets Ther; 2019; 12():2137-2147. PubMed ID: 30962695
    [TBL] [Abstract][Full Text] [Related]  

  • 23. CDK7 Inhibition is Effective in all the Subtypes of Breast Cancer: Determinants of Response and Synergy with EGFR Inhibition.
    McDermott MSJ; Sharko AC; Munie J; Kassler S; Melendez T; Lim CU; Broude EV
    Cells; 2020 Mar; 9(3):. PubMed ID: 32155786
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Coordinated targeting of CK2 and KIT in gastrointestinal stromal tumours.
    Huang M; Yang W; Zhu J; Mariño-Enríquez A; Zhu C; Chen J; Wu Y; Quan Y; Qiu H; Li X; Chai L; Fletcher JA; Ou WB
    Br J Cancer; 2020 Feb; 122(3):372-381. PubMed ID: 31776458
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A novel tyrosine kinase switch is a mechanism of imatinib resistance in gastrointestinal stromal tumors.
    Mahadevan D; Cooke L; Riley C; Swart R; Simons B; Della Croce K; Wisner L; Iorio M; Shakalya K; Garewal H; Nagle R; Bearss D
    Oncogene; 2007 Jun; 26(27):3909-19. PubMed ID: 17325667
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A Novel Receptor Tyrosine Kinase Switch Promotes Gastrointestinal Stromal Tumor Drug Resistance.
    Boichuk S; Galembikova A; Dunaev P; Valeeva E; Shagimardanova E; Gusev O; Khaiboullina S
    Molecules; 2017 Dec; 22(12):. PubMed ID: 29206199
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Therapeutic Rationale to Target Highly Expressed CDK7 Conferring Poor Outcomes in Triple-Negative Breast Cancer.
    Li B; Ni Chonghaile T; Fan Y; Madden SF; Klinger R; O'Connor AE; Walsh L; O'Hurley G; Mallya Udupi G; Joseph J; Tarrant F; Conroy E; Gaber A; Chin SF; Bardwell HA; Provenzano E; Crown J; Dubois T; Linn S; Jirstrom K; Caldas C; O'Connor DP; Gallagher WM
    Cancer Res; 2017 Jul; 77(14):3834-3845. PubMed ID: 28455421
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Targeting the WEE1 kinase strengthens the antitumor activity of imatinib via promoting KIT autophagic degradation in gastrointestinal stromal tumors.
    Liu W; Zeng X; Yin Y; Li C; Yang W; Wan W; Shi L; Wang G; Tao K; Zhang P
    Gastric Cancer; 2020 Jan; 23(1):39-51. PubMed ID: 31197522
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Resistance to c-KIT kinase inhibitors conferred by V654A mutation.
    Roberts KG; Odell AF; Byrnes EM; Baleato RM; Griffith R; Lyons AB; Ashman LK
    Mol Cancer Ther; 2007 Mar; 6(3):1159-66. PubMed ID: 17363509
    [TBL] [Abstract][Full Text] [Related]  

  • 30. THZ1 Reveals Roles for Cdk7 in Co-transcriptional Capping and Pausing.
    Nilson KA; Guo J; Turek ME; Brogie JE; Delaney E; Luse DS; Price DH
    Mol Cell; 2015 Aug; 59(4):576-87. PubMed ID: 26257281
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Inhibition of cyclin-dependent kinase 7 mitigates doxorubicin cardiotoxicity and enhances anticancer efficacy.
    Chen J; Wei J; Xia P; Liu Y; Belew MD; Toohill R; Wu BJ; Cheng Z
    Cardiovasc Res; 2024 Jul; 120(9):1024-1036. PubMed ID: 38646672
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Molecular research directions in the management of gastrointestinal stromal tumors.
    Tarn C; Godwin AK
    Curr Treat Options Oncol; 2005 Nov; 6(6):473-86. PubMed ID: 16242052
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Targeting CDK7 suppresses super enhancer-linked inflammatory genes and alleviates CAR T cell-induced cytokine release syndrome.
    Wei Y; Li C; Bian H; Qian W; Jin K; Xu T; Guo X; Lu X; Su F
    Mol Cancer; 2021 Jan; 20(1):5. PubMed ID: 33397398
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Activation of the p53 Transcriptional Program Sensitizes Cancer Cells to Cdk7 Inhibitors.
    Kalan S; Amat R; Schachter MM; Kwiatkowski N; Abraham BJ; Liang Y; Zhang T; Olson CM; Larochelle S; Young RA; Gray NS; Fisher RP
    Cell Rep; 2017 Oct; 21(2):467-481. PubMed ID: 29020632
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Identification of a Multitargeted Tyrosine Kinase Inhibitor for the Treatment of Gastrointestinal Stromal Tumors and Acute Myeloid Leukemia.
    Lin WH; Wu SY; Yeh TK; Chen CT; Song JS; Shiao HY; Kuo CC; Hsu T; Lu CT; Wang PC; Wu TS; Peng YH; Lin HY; Chen CP; Weng YL; Kung FC; Wu MH; Su YC; Huang KW; Chou LH; Hsueh CC; Yen KJ; Kuo PC; Huang CL; Chen LT; Shih C; Tsai HJ; Jiaang WT
    J Med Chem; 2019 Dec; 62(24):11135-11150. PubMed ID: 31721578
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Bromodomain and extraterminal domain inhibitor enhances the antitumor effect of imatinib in gastrointestinal stromal tumours.
    Mu J; Sun P; Ma Z; Sun P
    J Cell Mol Med; 2020 Feb; 24(4):2519-2530. PubMed ID: 31957165
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cyclin D1 is a mediator of gastrointestinal stromal tumor KIT-independence.
    Ou WB; Ni N; Zuo R; Zhuang W; Zhu M; Kyriazoglou A; Wu D; Eilers G; Demetri GD; Qiu H; Li B; Marino-Enriquez A; Fletcher JA
    Oncogene; 2019 Sep; 38(39):6615-6629. PubMed ID: 31371779
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The covalent CDK7 inhibitor THZ1 enhances temsirolimus-induced cytotoxicity via autophagy suppression in human renal cell carcinoma.
    Chow PM; Liu SH; Chang YW; Kuo KL; Lin WC; Huang KH
    Cancer Lett; 2020 Feb; 471():27-37. PubMed ID: 31812697
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Opposing roles of KIT and ABL1 in the therapeutic response of gastrointestinal stromal tumor (GIST) cells to imatinib mesylate.
    Rausch JL; Boichuk S; Ali AA; Patil SS; Liu L; Lee DM; Brown MF; Makielski KR; Liu Y; Taguchi T; Kuan SF; Duensing A
    Oncotarget; 2017 Jan; 8(3):4471-4483. PubMed ID: 27965460
    [TBL] [Abstract][Full Text] [Related]  

  • 40. BPR1J373, a novel multitargeted kinase inhibitor, effectively suppresses the growth of gastrointestinal stromal tumor.
    Tsai HJ; Jiaang WT; Shih NY; Fletcher JA; Lin MJ; Yang MY; Chen CT; Hsu TJ; Wu CC; Lin HY; Chen LT
    Cancer Sci; 2018 Nov; 109(11):3591-3601. PubMed ID: 30142229
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.